Equities research analysts forecast that West Pharmaceutical Services Inc. (NYSE:WST) will post sales of $428.40 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for West Pharmaceutical Services’ earnings. The highest sales estimate is $431.80 million and the lowest is $425.00 million. West Pharmaceutical Services reported sales of $398.20 million in the same quarter last year, which indicates a positive year over year growth rate of 7.6%. The business is expected to report its next quarterly earnings report before the market opens on Thursday, October 25th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full-year sales of $1.75 billion for the current financial year, with estimates ranging from $1.74 billion to $1.75 billion. For the next financial year, analysts anticipate that the business will post sales of $1.87 billion. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 26th. The medical instruments supplier reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.03. The company had revenue of $447.50 million during the quarter, compared to analysts’ expectations of $422.57 million. West Pharmaceutical Services had a return on equity of 15.38% and a net margin of 8.99%. West Pharmaceutical Services’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.66 earnings per share.
A number of research firms recently commented on WST. ValuEngine upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $135.00 price objective for the company in a research report on Saturday, October 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $110.50.
West Pharmaceutical Services stock opened at $113.91 on Wednesday. The firm has a market cap of $8.37 billion, a P/E ratio of 40.97, a PEG ratio of 3.86 and a beta of 1.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.67 and a quick ratio of 1.94. West Pharmaceutical Services has a one year low of $82.74 and a one year high of $125.09.
In related news, SVP Karen Flynn sold 20,458 shares of the company’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $116.23, for a total transaction of $2,377,833.34. Following the completion of the sale, the senior vice president now owns 31,051 shares in the company, valued at $3,609,057.73. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Integrated Investment Consultants LLC purchased a new stake in West Pharmaceutical Services in the second quarter worth about $155,000. First Allied Advisory Services Inc. purchased a new stake in West Pharmaceutical Services in the second quarter worth about $200,000. Alps Advisors Inc. purchased a new stake in West Pharmaceutical Services in the second quarter worth about $206,000. Grandfield & Dodd LLC purchased a new stake in West Pharmaceutical Services in the second quarter worth about $207,000. Finally, Wetherby Asset Management Inc. purchased a new stake in West Pharmaceutical Services in the second quarter worth about $223,000. Institutional investors and hedge funds own 93.63% of the company’s stock.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
See Also: Diversification For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.